---
source_path: H05CAR-PDF-ENG.md
pages: n/a-n/a
chunk_id: 8cb4c733866b42a403442dbbd1aaf2f64b34b50a
title: H05CAR-PDF-ENG
---
# Freudenthal Verhagen/Getty Images

In December 2000, when Dr. Tadataka Yamada became the new

chairman of research and development at Glaxo SmithKline, he was

horriﬁed to learn that his company was a complainant in a lawsuit

over access to drug therapies for HIV/AIDS patients. GSK was one

of 39 pharmaceutical companies charging Nelson Mandela and the

government of South Africa with violating price protections and

intellectual property rights in their eﬀorts to access lower priced

Copyright © 2019 Harvard Business School Publishing. All rights reserved.

1

This document is authorized for use only by Matt O'Donnell (matthew.od11@gmail.com). Copying or posting is an infringement of copyright. Please contact customerservice@harvardbusiness.org or 800-988-0886 for additional copies.
